News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Nature Index Identifies Top Contributors to Innovation
Catherine Offord | Aug 9, 2017
New rankings highlight institutions that have produced large numbers of articles cited in others' patents.
UC Berkeley: Patent Office “Ignored Key Evidence”
Jef Akst | Jul 26, 2017
The University of California files a brief in its appeal challenging the ruling that the Broad Institute’s group would retain its CRISPR genome-editing patent.
The Invention Return on NIH Investments
Kerry Grens | Apr 2, 2017
Around 8 percent of grants funded by the National Institutes of Health resulted in patents.
UC Berkeley Receives CRISPR Patent in Europe
Jef Akst | Mar 24, 2017
The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.
Broad Wins CRISPR Patent Interference Case
Jef Akst | Feb 15, 2017
The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.
Drug Approval Timeline Same as 20 Years Ago
Kerry Grens | Jan 9, 2017
A report finds that new medications still take about 12 years to go from patent to patient.
Repurposing Existing Drugs for New Indications
Anna Azvolinsky | Jan 1, 2017
An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.
Infographic: Repurposing Strategies
Anna Azvolinsky | Dec 31, 2016
Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.
Life Science Controversies of 2016
Bob Grant, Jef Akst, Tracy Vence | Dec 23, 2016
This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.